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ABSTRACT
IDENTIFYING MENSTRUAL SYMPTOM PATTERNS IN YOUNG WOMEN USING
FACTOR AND CLUSTER ANALYSIS
MAY 2015
FELICIA A. QUINTANA-ZINN, B.S., UNIVERSITY OF ARIZONA
M.B.A., UNIVERSITY OF PHOENIX
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Dr. Elizabeth Bertone-Johnson
Approximately 80% of reproductive age women experience physical or emotional
symptoms prior to onset of menses. Of these women, approximately 20% experience
symptoms severe enough to interfere with social functioning and life activities and meet
criteria for premenstrual syndrome (PMS). More than 100 different symptoms are
associated with PMS, the most common of which include breast tenderness, headache,
anger, and depression. Symptom groupings tend to be stable within an individual but can
vary distinctly between women. Potential differences in the etiology of symptoms
suggest that PMS should not be considered a single condition in research or clinical
studies, but rather may represent distinct entities that group by symptom patterns. The
primary goal of this study was to identify symptom patterns using factor and cluster
analysis. Analysis included: 1) a cohort of healthy women aged 18-30 (n =414); and 2)
the subgroup of women meeting established criteria for PMS (n=80). All participants
provided information on the occurrence and severity of 26 menstrual symptoms by
validated questionnaire. Four distinct symptom patterns emerged: Emotional,
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Psychological, Physical, and Consumption. Cronbach’s alpha levels demonstrating
reliability were high in both the total population (0.71 – 0.90) and in the PMS subset
(0.69-0.80). Additionally, cluster analysis identified 4 clusters in both the total
population and PMS subset. These symptom patterns were consistent with those
identified in prior studies in diverse populations. These observations suggest that distinct
subtypes of PMS may exist, and should be considered when recommending treatments
and evaluating risk factors.
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CHAPTER I
INTRODUCTION
Introduction
There are over 150 different premenstrual symptoms that are associated with a
woman’s menses covering a wide range of cognitive, behavioral, physical, and emotional
disturbances.1-3 Common examples of these symptoms include, but are not limited to:
confusion, mood swings, food cravings, breast tenderness, headache, abdominal
cramping, anger and depression.3-7 These symptoms are present in the luteal phase and
absent during the follicular phase of the menstrual cycle and can be present at any time
during the reproductive years of women. Symptoms usually last 3-5 days, but may
persist up to 10-14 days per month.1-2, 8-11
It is estimated that approximately 80% of women of reproductive age experience
physical or emotional premenstrual symptoms. 6, 8-9, 12-13 The prevalence of premenstrual
symptoms tends to increase in the mid-20s to the mid-30s.8 The symptoms and their
severity can vary substantially between women and many evaluations suggest stability
within a woman’s menstrual cycle which is important for being able to identify patterns. 34, 10, 14-16

An estimated 50% of women who experience symptoms seek medical care and

45% have asked for help with symptoms.8, 11-12, 17 It is estimated that the common
treatments for premenstrual symptoms have less than 60% efficacy. 8, 17 The most
common treatment options for women are selective serotonin reuptake inhibitors (SSRIs),
oral contraceptives, alprazolam, dietary supplements, and psychological treatments. 8-31 It
has been recommended by several studies that the identification of symptom clusters and
1

the identification of the underlying factors of these clusters will assist in clinical
diagnosis and possible personalization of treatments. 7-9, 14
Classification of PMS and Diagnostics
The prevalence of premenstrual symptoms in the general population is important
to understand, as is the prevalence in the sub-population of women that experience more
severe forms of disease, premenstrual syndrome (PMS) and premenstrual dysphoric
disorder.
The prevalence of PMS has been reported by the American College of
Obstetricians and Gynecologists (ACOG) to be between 15 to 20% of U.S. women of
reproductive age but has been reported to be as low as 8.3% and as high as 31%. 5, 20-21
Variations in diagnostic criteria and measurement instruments leads to inconsistency in
prevalence estimates. One example of the difficulty with diagnostics is that there are
guidelines from the ACOG and World Health Organizations (WHO) which are not
always consistent with each other. ACOG designated a set of diagnostic criteria for PMS
in 2000. The diagnostic criteria include experiencing (1) at least one affective and one
somatic symptom during the 5 days prior to menses during the 3 prior menstrual cycles,
(2) symptoms end within 4 days of the onset of menses and do not return until at least the
12th day of the cycle, (3) interfere with social, school, and work activities, and (4)
symptoms are present in the absence of pharmacological therapy, hormone ingestion, or
drug/alcohol use.42
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Pathophysiology of Symptoms
It is common for women to experience a cluster of symptoms for which one
treatment may reduce the severity of some of the symptoms but not all of the symptoms.
These symptom clusters can include a few symptoms to more than 10 distinct
symptoms.4, 7-9, 15-17 But many studies have found that even though the symptom
numbers may vary between women that the symptoms, particularly those that are more
severe, are persistent across cycles within women. 7-8, 19-20, 36 The pathophysiology of
premenstrual symptoms and PMS are not well understood but they are thought to be due
in part to cyclical changes in sex steroid hormones. For example, a spike in estrogen
levels occur in the follicular phase and a spike in progesterone levels occur in the luteal
phase prior to menstruation.10, 37-38 Symptoms that are described with the large fluctuation
in progesterone are generally mood disturbances. 37 But these changes most likely do not
account for the wide array of symptoms that are seen between women and even in the
same woman. 14,20,39
Some of the physical symptoms associated with PMS likely involve dysfunction
of the renin-angiotensin-aldosterone system (RAAS). This system is associated with
fluid and salt retention because it causes the adrenal glands to secrete aldosterone and has
been reported with symptoms like swelling of extremities and bloating of the
abdomen.18,21 While other menstrual symptoms like headache, muscle pain, and breast
tenderness, are not well understood.
It is proposed that some symptoms are affected by hormonal shifts while others
may be affected by changes in neurotransmitters.3,5,10,21,37-38 The severe emotional,
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cognitive, and behavioral premenstrual symptoms associated with PMS have been
hypothesized to be affected by changes in neurotransmitters. The neurotransmitter
serotonin has been examined in part because of pharmacological therapies, like selective
serotonin reuptake inhibitors (SSRIs), which utilize it as an antidepressant and anxiety
reducer. 10,14,20,28
Treatment of Premenstrual Symptoms and PMS
Currently, the diagnostic criteria set forth by ACOG and WHO, identify PMS as a
single disorder. This identification hinders effective treatments, treatment options for
individuals, and studies of the etiologic factors. Treatment options currently involve diet
change, behavioral modification, and pharmacological interventions. 9-10,18,21-24 The
dietary interventions include diet and nutrition restrictions/supplementations and the
behavioral interventions include psychological therapies. 9,18,21 The pharmacological
interventions include the use of SSRIs9-10, oral contraceptives9-10, gonadotropin-releasing
hormone agonists10, alprazolam9, and many others. 21 These treatment options are helpful
for some symptoms. For example, dietary treatments that include calcium22,25, B69,20,26,
and magnesium supplementation20,30 have shown to improve some symptoms. However,
supplementation of evening primrose oil has been shown to be ineffective in treating
symptoms.18,27 Clinical trials show that oral contraceptives are effective for some of the
somatic symptoms, such as breast pain and bloating, but these have also been shown to
have deleterious effects on psychological symptoms in some studies. 30 Additionally,
clinical trials that show SSRIs are effective for treating some of the emotional and
somatic premenstrual symptoms but long term use of these medications can be financially
costly and are known to have adverse effects.9,18,28
4

Economic Costs
With approximately 20% of U.S. women of reproductive age experiencing the
detrimental effects of PMS, it is expected that there would be societal and individual
economic costs in addition to the cognitive, behavioral, physical and emotional
disturbances. 5, 20-21 In 2005, one study estimated the direct and indirect economic costs.
The authors found that in addition to the direct medical costs of approximately $59 per
woman per year of PMS, there is an added estimated $4,000 in indirect costs per woman
per year.43 The extra indirect costs are attributed to reduced work productivity and missed
workdays. The low efficacy of treatments, severity of symptom complaints, and
economic burden on individuals and society indicate a need to further research new
methods of identification and diagnosis of premenstrual symptoms in both the general
population and in the sub-population of women that experience PMS.6,43-44
Epidemiology
Eight epidemiological studies have investigated premenstrual symptom clusters in
women. Three of these studies were cohorts 4,16,47; one was a population-based cross
sectional and comparative study17; three were cross-sectional48-50; and one a randomized
control double-blind crossover trial.51 Each study identified clusters or patterns of
symptom clusters however, each utilized a different number of symptoms in their
questionnaires ranging from 14 to 57 symptoms. Finally, of the studies, types of analysis
completed were as follows: cluster analysis8, rank-ordered3, and the majority of the
studies utilized factor analysis.16-17, 47-51
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The first, a 1986 study by Endicott et al4, used multiple methods to identify
clusters and determine if there were any underlying traits for women with PMS. The
study had a population of 64 women that were screened and excluded if they had
irregular menstrual cycles, current physical illness, taking medications, on birth control
pills, and were not between 18-45 years of age. The authors used a Daily Rating Form to
classify women into moderate-to-severe and minimal or no dysphoric premenstrual
changes from pre-menses to post-menses. The study utilized different analysis
techniques to identify premenstrual changes instead of one all-encompassing
premenstrual syndrome term. Using factor analysis, Endicott et al, identified 5 different
dimensions of premenstrual change that are possible underlying traits for women with
PMS through factor analysis, as shown in Table 1. The 5 dimensions were: (1) physical
discomfort, (2) more alcohol, sex, active, (3) low energy, (4) increased consumption, and
(5) dysphoric mood. In the second analysis method, cluster analysis, the authors, found
that there were 3 clusters that appeared to have the most clinical relevancy. Unlike the
factor analysis methods, Endicott et al., does not describe the clusters in detail and only
describes the number of individuals in each cluster (N=7, 32, & 25). Cluster analysis and
factor analysis results were utilized in the third analysis technique, in which they use a
summary scoring system. This system was based on the 5 factor pattern previously
described which was corroborated with the cluster analysis results in which they derive
patterns of symptom changes. The summary scoring system was then used to test the
association between the scores and lifetime diagnosis of major or minor depressive
disorder compared to no depressive disorder, in which they did not find significant chisquared results (4.4, df =0.4). Endicott, et al. used these patterns to describe that instead
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of using PMS as an all-encompassing term for severe premenstrual symptoms, it would
be better to identify underlying traits to better understand the biological factors, treatment
options, and diagnosis. The main limitation to this study was the small size of the study
population; which may have limited the ability to fully classify the true underlying
factors of the study population. 4
The second study was a 1995 study by Gotts et al16, which utilized rank-ordering
of symptoms to identify the differences in PMS symptoms and severity within a cycles
and define particular unique patterns of experiences. The population in this study
included 98 women age 18-45 years of age that had complaints of mood, behavioral, and
physical changes 10 days prior to menstruation, complaints abated at or during
menstruation followed by a week of no/minimal symptoms, experienced regular
menstruation and occurrence of symptoms over the prior 6 cycles, and did not have
underlying psychiatric disorders, and did not receive psychotropic medication,
psychotherapy or hormone therapy. The participants completed the Moos Menstrual
Distress Questionnaire (MDQ) for 2 consecutive cycles. The study used 2 categories of
symptoms, psychological and physical symptoms, with the top 4 severe symptoms of
concern defining each woman’s premenstrual experiences. Example psychological
symptoms were: affective (irritability, mood swings); behavioral (crying, yelling); and
cognitive (confusion, distractibility). Physical symptoms were: pain-related (headache,
sore breasts); and non-pain related (change in appetite, altered motor function). The
experiences were ranked by the severity of the symptoms. The authors then used the
rank-ordered data to analyze which severe symptoms were most commonly experienced
by the women and used the two category data to develop 16 possible premenstrual
7

experiences. 16 Gotts et al., reported that over 70% of the participants reported their most
severe symptom as a psychological problem, which was most commonly reported to be
irritability. However, the authors did not list the symptoms or rankings in the journal
article and it is not possible to determine the most common or severe and therefore limits
the interpretability of this study. The main limitation in this study is the small study
population. 16 Additionally, the main purpose of this study was to identify that there were
separate and distinct patterns of experiences but not to identify the underlying cause or
clusters of symptoms. 16
In the largest study to date, Woods et al17, attempted to identify clusters of
premenstrual symptoms and the reproducibility of these symptoms versus a comparison
population of women that were selected with low-severity symptoms and PMS in 1999.
The study used two populations, the first included 345 women in a cross sectional study,
aged 18-45 years of age from a northwestern metropolitan city who completed a daily
health diary for at least one full menstrual cycle. Inclusion criteria included that they
were not currently pregnant, not treated for a gynecological problem, and had menstrual
periods. The second sample included 118 women in a comparative study that were
between 18-45 years of age. Exclusion criteria were taking oral contraceptives/ other
ovarian hormones, antidepressants, tranquilizers, diuretics, hypertension medications,
corticosteroids, and were not pregnant or lactating. The women completed the
Washington Women’s Health Diary (WWHD) which included 57 menstrual symptoms
derived from multiple symptom questionnaires including the previously mentioned
MDQ. The main result of this study was the identification of 4 main constellations of
symptoms derived from factor analysis, which were titled: 1) turmoil, 2) fluid retention,
8

3) somatic, and 4) arousal symptoms. Unlike the previously described studies by
Endicott et al. and Gotts et al., the study by Woods et al., was the one of the only
epidemiological studies to provide detailed information on the variance of symptoms that
the patterns or groupings for the specific populations in each study described. The
authors reported, together the 4 symptom factors accounted for 42% of the variance of
symptoms. Individually, turmoil accounted for 23.8% of the variance, fluid retention for
6.8%, somatic for 5.8% and arousal for 5.2%. Four symptoms did not load into any of
the four patterns: cramps, hot flashes, sleepiness, and backache. The main limitation of
this study was that the daily health diary included information for one menstrual cycle
and did not include multiple menstrual cycles. Additionally, current depression status
was not taken into consideration which is important when psychological symptoms are
assessed during PMS and only factor analysis was completed. 17
Finally in the remaining five studies 47-51, the study populations ranged from 33 to
423 participants aged 15-48 years and each of these studies utilized factor analysis as the
only analysis completed. Similar to Woods et al and Endicott et al, each of the studies
identified between 4- and 6-factor patterns 48-51 with the exception of York et al46, in
which 2-factor patterns were extracted, but symptoms were not detailed by York et al.
Additionally, the studies that detailed the symptoms in the patterns had emotional and
cognitive symptoms loading strongly to the first pattern; many studies reported a water
retention pattern and physical patterns in their main results. 16-17, 48-51
There is an overlap in the symptom clusters that are identified in six of the eight
studies 16-17, 48-51, even with different methodologies and symptoms reported. These
studies demonstrated that symptoms have common patterns or underlying traits that arise
9

when looking across studies with different populations, questionnaires, and study
designs. However, due to small sample sizes in several of the studies, clearly defined
patterns that explain a large amount of variance of the symptoms have not been
determined.
We utilized two methods, cluster and factor analysis, to identify premenstrual
symptom patterns and examine if the identified patterns hold true for women in the
sample population and the sub-population that meet criteria for PMS in two University of
Massachusetts studies. The study helps to identify patterns in premenstrual symptoms in
women of reproductive age which may aid in the establishment of targeted treatments for
premenstrual symptoms. This is particularly important for women that have more severe
symptoms that can be debilitating such as those with PMS in which the efficacy of
treatments has been shown to be less than 60%. We examined population-based
information for women that experience general premenstrual symptoms and women that
meet the criteria for PMS as opposed to prior studies that have evaluated only one or the
other.

10

CHAPTER II
STUDY DESIGN AND METHODS
Study Population
We examined premenstrual symptoms for clusters and possible underlying factor
patterns using data from two studies of menstrual symptoms conducted at the University
of Massachusetts. These studies enrolled a total of 414 young women 18 to 30 years of
age from 2006 to 2014. Participants were recruited through advertisements posted
around the University of Massachusetts campus in Amherst, MA. All study
measurements were completed in one clinic visit which were based on the participant’s
date of next menstrual period. To confirm the luteal phase time the date of the next
menses was subsequently reported. The study questionnaires measured demographics,
behavioral, dietary and medical factors including menstrual symptoms and PMS.
Eligibility was limited to women currently menstruating and were not pregnant that did
not report a history of the following: high blood pressure, elevated cholesterol, kidney or
liver disease, bone disease such as osteomalacia, digestive disorders, rheumatologic
disease, multiple sclerosis, thyroid disease, hyperparathyroidism, cancer, type 1 or type 2
diabetes, polycystic ovaries, or current use of corticosteroids, anabolic steroids,
anticonvulsants, cimetidine, or propranolol.
Assessment of Menstrual Symptoms
Information was collected on current menstrual symptom experiences
using a questionnaire based on the Calendar of Premenstrual Experiences (COPE)
designed by Mortola et al and is similar to the questionnaire used in the Nurses’ Health
11

Study 2 (NHS2).2-3,23,25,52 Participants were given a list of 26 behavioral, physical, and
affective menstrual symptoms, detailed in Table 1. For each symptom listed, participants
were asked if they experienced it “most months of the year, for at least several days
before your menstrual period begins”, and to rate the usual severity of the symptom. 35
The severity of the individual symptoms was assessed using four categories: none, mild,
moderate or severe. Additionally, the women were asked to classify the overall severity
of their symptoms as: minimal (no effect on normal activities), mild (noticeable but not
troublesome), moderate (interferes with normal activities), or severe (intolerable and
prevents activities).
To assess the effect of menstrual symptoms on life activities and interpersonal
relationships, the participants were asked if they have experienced relationship discord
with a spouse or partner, difficulties parenting, poor work performance/attendance and/or
social isolation. For each woman if a positive response to one aspect was indicated, then
they were asked to classify the severity of the issue as: 1) not a problem, 2) mild, 3)
moderate, or 4) severe. Furthermore, the participant was asked if she had received a
clinical diagnosis of PMS.
To determine if the symptoms were associated with other psychiatric conditions
that are similar to PMS, women were asked if they had a history of depression, bipolar
disorder, or other psychiatric disorders, and if they were currently using anti-depressant
medications. The General Depression 20-item Sub-scale of the Inventory of Depression
and Anxiety Symptoms (IDAS) was added to the questionnaire in 2008 and was
completed by 102 participants and was used to identify women meeting criteria for
depression.35,53 These women were not excluded from study participation or from the full
12

cohort, but if IDAS score was greater than 50, it was an exclusion criteria for the subset
of participants meeting the criteria for PMS. A score greater than 50 suggests a
psychiatric disorder that may not yet be diagnosed. The IDAS scores were utilized as a
characteristic of the study participants as an additional factor that may be needed for
future analyses and the scoring system is detailed elsewhere. 35,53
In order to identify women who met the criteria for PMS, we identified women
meeting the following criteria: (1) experiencing at least one physical and one affective
menstrual symptom; (2) symptom severity of “moderate” or “severe”, the impact on life
activities and relationships of “moderate” or “severe” or at least one symptom rated as
“severe”; (3) symptoms being within 14 days to the start of menses; symptoms end within
7 days of the start of menses; (4) symptoms are absent in the week after menses; (5) no
evidence of a comorbid psychiatric disorder including IDAS score greater than 50.23,40,42
Validity of Methods for Identifying PMS Cases
Validity of our method of identifying PMS case classification made by BertoneJohnson et al23 in which direct comparison of the questionnaire method and prospective
symptom charting was completed. Forty-one women completed the modified COPE
questionnaire in the late-luteal phase of their menstrual cycles. The participants then
completed a daily symptom diary utilizing the standard COPE questionnaire for the
following cycle. A single blinded observer reviewed the diaries and questionnaires in a
random order and categorized the women as meeting the criteria for PMS cases, controls
or neither. Bertone-Johnson et al. reported that the sensitivity of the modified
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questionnaire compared to the prospective symptom diaries to identify PMS cases was
73%, and the positive predictive value of PMS cases was 80%. 23
Statistical Analysis
General descriptive statistics of study participants were calculated through the use
of summary statistics for age (years), BMI (kg/m 2), age at menarche (years), physical
activity (MET/week), IDAS scores, race, Latina ethnicity, education level, current usage
of oral contraceptives, smoking status both ever and current usage, marijuana use, current
use of anti-depressants, and current use of multivitamins; detailed in Table 2.
Factor analysis techniques were used to identify the possible underlying patterns
for all premenstrual symptoms and their severity experienced. 53-54 Exploratory factor
analysis was completed in both the full cohort and the subset of participants that met the
criteria for PMS independently utilizing the principle components method and procedure
FACTOR in SAS. 53-54 To determine the number of factor patterns to extract, three
standard methods and criteria were used for both populations: (1) Kaiser-Guttman (K1)
rule in which factors with eigenvalues greater than 1.00 are considered, (2) Cattell scree
plot in which factors are plotted against eigenvalues in descending order of magnitude are
displayed and was used to identify a distinct break in the slope, and (3) parallel analysis
(PA) which uses a iterative process to determine if eigenvalues displayed are due to
sampling error by comparing random eigenvalues to observed eigenvalues; this aids in
extracting patterns that provide meaningful components to extract from the data. 53-54 In
the event in which the 3 criteria for extraction do not result in the same number of
patterns, extraction pattern values were utilized as a range and the following criteria for
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factor loading and pattern retention were utilized to determine the specific number of
patterns to retain (e.g. K1 and scree plot identify 4-factor patterns and PA identifies 6factor pattern; extraction for loading and retention will be performed on 4-, 5-, and 6factor patterns). The following 3 criteria for factor loading and pattern retention were
utilized: (1) symptoms were considered as loading strongly and were retained for
loadings >30; (2) a minimum of 3 symptoms were required for each factor pattern to be
considered for retention; and (3) if more than 1 symptom loaded strongly to multiple
factors the factor with the highest loading was retained. 53-54 Any symptoms not loading
strongly to any of the factor patterns were removed from further analysis. To aid in the
interpretability of factor patterns, Varimax rotation of symptoms was utilized and factor
scores were provided for each of the symptom which was consistent with prior literature
7,16-17,47-51,53-54

(Tables 3-5). After factor patterns were extracted and identified,

reliability tests were completed for each factor utilizing Cronbach’s alpha 53-54 (Tables 6
and 7). Additionally demographic and cohort characteristic were provided for each of
the factor pattern and were stratified by score quartiles. Continuous demographic
variables were compared between factor patterns by ANOVA tests and categorical
variables were compared using Chi-square or Fisher’s exact tests in both the full cohort
and subset (Tables 8 and 9).
Additionally, linear relations between factor patterns and BMI, total energyadjusted folate and total energy-adjusted niacin were assessed, with results shown as
Pearson correlation coefficients presented in Tables 10 and 11.
Non-hierarchical cluster analysis was used to group individuals into subgroups,
otherwise known as clusters. 54-55 The groups of individuals cluster by having experienced
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similar symptoms and similar severity of these symptoms. Unlike factor analysis, each
woman may only belong to one cluster. The clusters were identified by utilizing the data
provided by each woman regarding the symptoms and severity experienced using kmeans and the procedure FASTCLUS in SAS. 54-55 The number of clusters was
determined through a stepdown method starting with 20 clusters to the final 4 clusters.
To retain a particular amount of clusters in each run, each cluster needed to have a
minimum of 3 participants to ensure there were not too many clusters for interpretation of
the results. Tables 12 and 13 demonstrate the demographic and cohort characteristics for
each of the clusters in both the full cohort and subset. ANOVA tests were completed for
each of the continuous demographic variables and Chi-square or Fisher’s exact tests were
completed for each of the categorical variables. Table 14 and 15 demonstrate the mean
scores for each factor pattern along with ANOVA tests. In addition Figures 15-22
display the distribution of factor values for the participants in each of the clusters in both
the total study population and in the subset meeting criteria for PMS.
All analyses were completed using SAS Version 9.4.
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CHAPTER III
RESULTS
General Information
The demographic characteristics of all study participants (n=414) and the subset
of the women who meet the criteria for PMS (n=80) are displayed in Table 1. The mean
age of the participants in the total population was 21.0 years and in the subset 20.9 years.
The majority of study participants reported white race (82.3%) with a small proportion
reporting Hispanic ethnicity (6.8%). Study participants meeting criteria for PMS
reported slightly higher use of oral contraceptives, being ever/current smokers, and
smoking marijuana. The premenstrual symptoms reported by all study participants are
displayed in Figure 1 and the subset of women meeting criteria for PMS in Figure 2.
Factor Analysis
As discussed above, exploratory factor analysis (EFA) was completed in both the
full cohort and subset independently. In the full cohort, all 3 methods and criteria
suggested that a 4-factor pattern was to be extracted, as displayed in Figure 3. Utilizing
the procedure FACTOR and the aforementioned Varimax rotation, symptoms were given
factor loading scores to reflect their contribution to each of the 4-factor patterns. Of the
26 symptoms reported, 2 symptoms (hot flashes and swelling of extremities) did not load
strongly (i.e. loading >30) on any of the factor pattern and therefore were removed from
subsequent analysis. Upon removal, variance for the factors was reviewed again, and
found not to have been affected by the removal of these symptoms and therefore 24
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symptoms remained. Factor loading and rotation was completed again for these 24
symptoms only. Factor loadings and scores are reported in Table 4 and 5.
In the subset of women meeting criteria for PMS, the 3 extraction methods and
criteria had differing results. K1 demonstrated 8 factors with eigenvalue >1; the scree
plot displayed a break in slope at 4 and 6 factors, and PA demonstrated 6 factors results
are displayed in Figure 4. It was determined that 8-factor patterns would be a viable
starting point for factor analysis and Varimax rotation. Under the 8-, 7-, and 6-factor
patterns, 2 symptoms (hot flashes and swelling of extremities) did not load strongly (>30)
and were removed from subsequent analysis (as occurred in the full cohort analysis).
After removal of the 2 symptoms, factor loading and rotation was completed for the
remaining 24 symptoms. In the 8- and 7-factor patterns, only factors 1-4 met the factor
loading and retention criteria and were therefore dismissed. In the 6-factor pattern, factors
5 and 6 did not meet the criteria for having at least 3 symptoms loading strongly. The
above process was repeated for a 5-factor pattern (Table 4) and a 4 factor pattern (Table
5). Under both patterns all 3 of the factor loading and pattern criteria were met.
Factor patterns were named in a descriptive manner for the overall interpretation
and comparability with previous studies. An example is, if a pattern has mood swings,
emotional hypersensitivity, and tendency to cry easily; a pattern name of “emotional”
would describe the overall symptoms experienced in this pattern.
To determine which factor pattern would be retained for the PMS subset,
reliability and interpretability of the factors were considered. Reliability tests were
completed for the 3 factor patterns retained, 4-factor full cohort pattern and the 5- and 4-
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factor pattern in the subset. Cronbach’s alpha (α) was utilized to reviewing the average
correlation of the set of the symptoms in each pattern. For this metric, α<0.60 is
considered poor, 0.60≤α<0.70 is considered acceptable, 0.70≤ α<0.80 is considered good,
and α≥0.90 is considered excellent. 53-54 Table 6 displays the 4-factor pattern for all
participants along with symptoms and factor loading scores for each symptom. All
patterns were observed to have reliability estimates in the good to excellent range:
Emotional (α=0.90), Psychological (α=0.83), Physical (α=0.74) and Consumption
(α=0.71). Table 7 displays the 5-factor pattern for women meeting criteria for PMS and
Table 8 displays the 4-factor pattern for this subset. In the 5-factor pattern alpha levels
were considered poor in the General Physical Pattern and averaged lower than the levels
in the 4-factor pattern, additionally, the 4-factor pattern also provides better
interpretability of the factors. We thus opted to retain the 4-factor pattern for further
analysis.
The 4-factor patterns identified in the full cohort were similar in symptoms
experienced to those of the PMS subset, with the exception of fatigue, abdominal
bloating, headache, and dizziness. The remaining 20 symptoms loaded into the same
symptom patterns in both the total population and PMS subset. These 4 patterns
explained 58.4% of the variance in the full cohort and 48.6% in the PMS subset. For each
pattern, women were classified into quartile based on factor scores. We then evaluated
how demographic and behavioral characteristics varied by factor scores (Tables 9 and
10). Table 9 shows the characteristics participants in the full cohort by quartile of each of
the four symptom patterns. IDAS Score (p-value <0.001) and current multivitamin usage
(p =0.02) varied statistically significant between quartiles of Emotional pattern. The
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Psychological symptom pattern, was associated with IDAS Score (p <0.001) and
reporting white race (p =0.02). Only reporting white race (p =0.01) was significantly
associated with quartile of the factor corresponding to physical symptoms. Finally, BMI
(p =0.01), physical activity (p =0.02), IDAS score (p <0.001), and ever having smoked (p
=0.03) were significantly related to levels of the consumption pattern. Table 10 displays
the above described comparison of characteristics by quartiles of the four symptom
patterns by restricted to the subset of those who met the criteria for PMS. In these
comparisons, associations were observed between the Emotional pattern and college was
significant (p =0.05); Psychological pattern, and IDAS score (p =0.002); Physical pattern
and physical activity (p =0.04) and IDAS score (p=0.02); and finally, between
Consumption pattern reporting white race (p =0.02).
Factor Analysis with BMI, total folate and total niacin correlations
Table 11 demonstrates correlation coefficients of the factor scores for each of the
4-factor with BMI, total energy-adjusted folate, and total energy-adjusted niacin 3 factors
previously observed to be associated with prevalence of PMS in this population. In the
full cohort, BMI was significantly associated with factor scores for Consumption (0.11,
p=0.03), but not other factors. Niacin intake was marginally associated with
Consumption score as well. Folate intake was not correlated with factor score for any of
the 4 patterns. Table 12 demonstrates correlation coefficients in the subset, in which BMI
was significantly associated with the factor scores for Consumption (0.22, p=0.05).
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Cluster Analysis
As discussed above, cluster analysis (CA) was completed in both the full cohort
and the subset independently. The FASTCLUS procedure was used to perform nonhierarchical CA on both the full cohort and subset to determine membership for each
cluster for a set number of clusters. Upon analysis of clusters identified, those with fewer
than 3 people were removed. Four clusters were retained for both the full cohort and the
PMS subset. Figures 5 and 6 graphically display the distribution of participants in both the
full cohort and the PMS subset, respectively. Figures 7-10 display the distribution of
symptoms and severity of symptoms reported by all participants in each of the 4 clusters.
Figures 11-14 display the distribution of symptoms and severity reported by the PMS
subset in each of the final 4 clusters.
In the full cohort, Cluster 1 (n=187), Cluster 2 (n=75), Cluster 3 (n=102), and
Cluster 4 (n=50) were identified; Table 13 shows the characteristics of women in each of
these four clusters. Mean age at menarche (p=0.02), IDAS score (p<0.001), and white race
significantly (p<0.001), differed across clusters and current anti-depressant use was
significant (p =0.05) higher in Cluster 4 than in the other 3 clusters.
Table 14 displays characteristics in the PMS subset, Cluster 1 (n=30), Cluster 2
(n=7), Cluster 3 (n=23), and Cluster 4 (n=20). When comparison characteristics of women
across clusters, ever having smoked was found to be significantly different (p=0.03) while
differences in IDAS score were marginally higher in Cluster 3 than Cluster 1 (p=0.07).
Table 15 displays the mean factor pattern scores and standard deviation of all
participants based on cluster. When the patterns were compared across clusters, each
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pattern was found to be significantly different for each of the four factor patterns (p<0.001).
Table 16 displays mean factor scores and standard deviation of participants meeting the
criteria for PMS based on cluster. As with the total study population, each pattern was
found to be significantly different for each of the four factor patterns (p<0.001).
In Figures 15-18 the distribution of factor scores is for each cluster is displayed in
boxplots. The distribution of Factor 1 displays Clusters 2 and 4 with higher overall mean
scores than in Clusters 1 and 3. Factor 2 displays Cluster 4 having higher overall scores
than in the other clusters. In Figures 19-22 the distribution of factor scores varies between
all of the clusters.
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CHAPTER IV
DISCUSSION
In our study, four factor patterns emerged in the full cohort of women and in the
PMS subset. We identified 4 symptom patterns in both the full cohort and the PMS
subset. Based on the factor loadings of the individual symptoms used for analysis, we
labeled these symptom patterns as Emotional, Psychological, Physical and Consumption.
The symptoms that contributed the highest loading scores in each of the four symptoms
were similar to symptom patterns reported in prior studies. 4,16-17, 47-51 As in prior
epidemiological studies, the symptoms that loaded strongly onto the Emotional pattern
and the Psychological pattern had the strongest loadings of the 4 factors and the highest
reliability scores of the four patterns (Emotional α=0.9 in the total study population and
0.8in the subset); Psychological (α=0.83 in the total study population and 0.78 in the
subset). Additionally, the symptoms that loaded into the Physical pattern also tend to
cluster together across many of the studies. 4, 16-17, 47-51
Our results were relatively consistent with the previous studies by Endicott et al,
Woods et al, Siegel et al, Alivir et al, and Chaturvedi et al. Many of these studies had
cohorts of women across the United States4, 16-17, 47-49, 51 and one study in India50, and
included women from the general population and those that met the criteria for PMS.
One major difference in the factor pattern results between our study and previous
analyses was the Consumption pattern. While this was similar to the factor patterns
found by Endicott et al and Alivir et al, it was not identified in other studies. First, the
existing studies have differed substantially regarding the specific menstrual symptoms
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assessed on study questionnaires and the total number of symptoms provided to
participants (ranging from 14-57 distinct symptoms). Other factors that might also
contribute to the differences can include the other treatments; oral contraceptive usage of
participants varied among prior studies, many of which studies did not have the same
exemption criteria for participants. 16-17, 48-51
Overall, the patterns we identified seem to be generally consistent with other
studies in both clinical and non-clinically presenting participants. However, the
symptoms hot flashes and swelling of the extremities did not load into any of our factor
patterns, unlike in three of the previous studies.17,49-50 These studies only included one of
the two symptoms on the questionnaires but not both. In the studies by Woods et al and
Chaturvedi et al swelling of the extremities fell into the fluid retention categories with
breast pain/engorgement and weight gain, bloating, acne, and increased sexual desire. 17,51
Additionally, hot flashes was only included in one other study, Siegel et al, in which it
was retained in the physical discomfort pattern with other symptoms like cramps,
backache, nausea, and dizziness/fainting.48 Due to differences in questionnaire and cohort
characteristics further research is needed.
Finally, an interesting piece, is that in each study between 4 and 6 patterns were
extracted from the data gathered from individuals in the general population studies and
also in studies that focused primarily on women that met the criteria for PMS. 16-17,48-49,51
This may provide further evidence that the general patterns of symptoms may indeed
have a latent or physiologic construct and may not be just a random occurrence.
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In addition to the EFA the 4 factors derived were utilized to test the correlations
between known risk factors. BMI was found to have a weak but statistically significant
relation with the Consumption pattern score. Consideration of how risk factors are
correlated with symptom patterns of in more depth, to see which symptoms are related,
illustrates the potential benefit of factor analysis for the development of interventions.
When we utilized cluster analysis techniques to determine constellations of
women, four clusters were identified in the full cohort and also in the PMS subset.
Unlike the factor patterns that were derived, the results from the cluster analysis provided
were difficult to interpret. For example, in the full cohort the women that were clustered
into Cluster 1 tended to either have no symptoms or mild symptoms reported, but Cluster
3 tended to report mild to moderate Physical and Emotional symptoms. Additionally, in
the PMS clusters, Cluster 1 participants were most likely to report mild to moderate
Physical and Emotional symptoms and Cluster 2-4 were likely to report moderate or
severe Physical, Emotional, Cognitive, and Psychological symptoms. Upon further
analysis, IDAS score was statistically significant when comparing the women across the
different clusters in both the full cohort and PMS subset. White race, age at menarche,
use of anti-depressants, and ever having smoked were found to be significant in either the
full cohort or the PMS subset but not in both. The comparison of clusters and mean
factor scores was helpful in understanding that there were differences between the
clusters and the overall symptom patterns experienced however; further analysis of
additional characteristics might be needed to fully understand the potential utility of the
clusters.
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The main limitations of factor analysis are that there are several decisions that are
made in the process that are arbitrary but still important, and patterns derived can vary
due to population characteristics. Some of the decisions made include determining the
number of factors to extract, the method of rotation chosen, and the labelling of the new
patterns with the number of factors to extract and the method of rotation chosen being of
the highest consequence. If we chose too many or too few factors, the symptoms loading
could be impacted, which could limit the insights into underlying patterns. In order to
minimize the effect that these two decisions have on the findings, we utilized several
known and well established methods of extracting patterns in order to make this decision.
These 3 methods provided similar numbers of patterns to extract, which were also in
agreement with the prior literature. Finally the patterns derived can vary due to other
characteristics of the study population such as age and diet. While this may be an issue,
our study findings are consistent with those from studies with very different populations,
including participant ages varying between 15-48 years of age, well beyond the ages of
our study, and from cohorts around the U.S. and one in India. 4, 16-17, 47-51 These
observations suggest that these are fairly consistent symptom patterns experienced in
multiple populations and when measured by many different tools.
The main limitations of cluster analysis are similar to that of factor analysis in that
he clusters are dependent on the participant characteristics and can vary due to specific
demographics like age or socioeconomic status. Additionally, cluster analysis will
always provide mutually-exclusive groupings of participants. Unfortunately due to lack
of studies using cluster analysis it is difficult to determine if the clusters in this study are
similar to other studies with similar participant characteristics.4 Further research is
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needed to determine if these clusters are meaningful or if they are specific to this one
population.
General study limitations include non-differential misclassification of the
symptoms and generalizability. In this study a non-differential misclassification of the
symptoms can occur at two points. First the information gathered on the symptoms was
provided cross-sectionally and the women were asked to recall the symptoms, frequency,
and severity. Although this would directly impact our symptom patterns, the
questionnaire utilized has been previously validated and found to have fairly high
sensitivity. 23 Secondly, there are over 100 possible distinct symptoms that women may
experience and our questionnaire was limited to 26. 23 However, the questionnaire used
has been derived from open-ended symptom diaries and reflects the most common and
important symptoms from these diaries. Therefore, these two issues of non-differential
misclassification of the symptoms are likely to be minimal in magnitude and of little
consequence to the results.
Finally, the generalizability of our study may also be a limitation; our study
population is fairly homogenous with a majority of the women reporting white race and
between ages 20 and 22. There may be some physiologic differences in women that are
substantially younger or older with either different symptom patterns or etiologic factors
affecting these age groups. However, as previously mentioned, the results from factor
analysis patterns have been fairly consistent across studies, study populations, and use of
multiple measurement tools.
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CHAPTER V
CONCLUSION
In conclusion, the factor analysis patterns that were identified in this study
provide interesting results that have been fairly consistent from study to study. These
results suggest that there are between four and six symptom patterns that are routinely
extracted with similar constellations of symptoms in these patterns. Further research is
needed to provide detailed information on whether these patterns are anomalies or if they
are driven by specific etiologies. Preferably this research would performed in a
heterogeneous population spanning all ages of reproductive women using one
measurement tool. Additionally, this information may be useful in understanding how
different risk factors are correlated with these patterns to better understand the etiology of
these symptoms.
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